JP2017505809A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505809A5 JP2017505809A5 JP2016563894A JP2016563894A JP2017505809A5 JP 2017505809 A5 JP2017505809 A5 JP 2017505809A5 JP 2016563894 A JP2016563894 A JP 2016563894A JP 2016563894 A JP2016563894 A JP 2016563894A JP 2017505809 A5 JP2017505809 A5 JP 2017505809A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- hepe
- free acid
- weight
- fatty acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- WLKCSMCLEKGITB-XWJJKCKWSA-N 15-HEPE Chemical compound CC\C=C/CC(O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O WLKCSMCLEKGITB-XWJJKCKWSA-N 0.000 claims description 9
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 150000004665 fatty acids Chemical class 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 239000002253 acid Substances 0.000 claims 7
- 239000002775 capsule Substances 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Description
別の実施形態では、１５−ＨＥＰＥは、本発明の組成物中に存在する全ての脂肪酸の少なくとも約６０重量％、少なくとも約７０重量％、少なくとも約８０重量％、少なくとも約９０重量％、少なくとも約９５重量％、少なくとも約９７重量％、少なくとも約９８重量％、少なくとも約９９重量％、または１００重量％を表す。
別の実施形態では、１５−ＨＥＰＥは、本発明の組成物中に存在する全ての脂肪酸の少なくとも約６０重量％、少なくとも約７０重量％、少なくとも約８０重量％、少なくとも約９０重量％、少なくとも約９５重量％、少なくとも約９７重量％、少なくとも約９８重量％、少なくとも約９９重量％、または１００重量％を表す。
Claims (10)
- 必要な対象において、慢性閉塞性肺疾患（COPD）を治療するための医薬組成物の製造における、１５−ＨＥＰＥ遊離酸100mgから約1,000mgの使用であって、該医薬組成物が毎日投与されるように調剤されており、該１５−ＨＥＰＥ遊離酸が、該医薬組成物中に存在する全ての脂肪酸の少なくとも約60重量％を表す、前記使用。
- 前記医薬組成物が投与量単位中に存在する、請求項１記載の使用。
- 前記投与量単位がカプセルである、請求項２記載の使用。
- 前記１５−ＨＥＰＥ遊離酸が、前記医薬組成物中に存在する全ての脂肪酸の少なくとも約90重量％である、請求項１記載の使用。
- 前記１５−ＨＥＰＥ遊離酸が、前記医薬組成物中に存在する全ての脂肪酸の少なくとも約95重量％である、請求項１記載の使用。
- 前記医薬組成物が、前記１５−ＨＥＰＥ遊離酸400mgから約700mgを含む、請求項１記載の使用。
- 前記医薬組成物が投与量単位中に存在する、請求項６記載の使用。
- 前記投与量単位がカプセルである、請求項７記載の使用。
- 前記１５−ＨＥＰＥ遊離酸が、前記医薬組成物中に存在する全ての脂肪酸の少なくとも約90重量％である、請求項６記載の使用。
- 前記１５−ＨＥＰＥ遊離酸が、前記医薬組成物中に存在する全ての脂肪酸の少なくとも約95重量％である、請求項６記載の使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461926052P | 2014-01-10 | 2014-01-10 | |
| US61/926,052 | 2014-01-10 | ||
| PCT/US2015/011054 WO2015106215A2 (en) | 2014-01-10 | 2015-01-12 | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019149177A Division JP2020002150A (ja) | 2014-01-10 | 2019-08-15 | １５−ｈｅｐｅを含む薬学的組成物ならびにこれを用いた喘息及び肺障害の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017505809A JP2017505809A (ja) | 2017-02-23 |
| JP2017505809A5 true JP2017505809A5 (ja) | 2019-02-14 |
Family
ID=53520398
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016563894A Ceased JP2017505809A (ja) | 2014-01-10 | 2015-01-12 | １５−ｈｅｐｅを含む薬学的組成物ならびにこれを用いた喘息及び肺障害の治療方法 |
| JP2019149177A Pending JP2020002150A (ja) | 2014-01-10 | 2019-08-15 | １５−ｈｅｐｅを含む薬学的組成物ならびにこれを用いた喘息及び肺障害の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019149177A Pending JP2020002150A (ja) | 2014-01-10 | 2019-08-15 | １５−ｈｅｐｅを含む薬学的組成物ならびにこれを用いた喘息及び肺障害の治療方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20150196521A1 (ja) |
| EP (1) | EP3091959A4 (ja) |
| JP (2) | JP2017505809A (ja) |
| KR (1) | KR20160132372A (ja) |
| CN (1) | CN106029051A (ja) |
| AU (1) | AU2015204531B2 (ja) |
| BR (1) | BR112016015997A2 (ja) |
| CA (1) | CA2935986A1 (ja) |
| IL (1) | IL246623A0 (ja) |
| MX (1) | MX2016008953A (ja) |
| PH (1) | PH12016501371A1 (ja) |
| RU (2) | RU2685706C2 (ja) |
| SG (2) | SG11201605601UA (ja) |
| WO (1) | WO2015106215A2 (ja) |
| ZA (1) | ZA201605492B (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ702325A (en) | 2012-05-10 | 2016-09-30 | Solutex Na Llc | Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors |
| CN105899485B (zh) | 2013-11-15 | 2018-10-19 | 尊严科学有限公司 | 多不饱和羟基脂肪酸的药学上可接受的盐 |
| ES2851525T3 (es) * | 2015-07-21 | 2021-09-07 | Afimmune Ltd | Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia |
| WO2017041094A1 (en) | 2015-09-03 | 2017-03-09 | Solutex Na Llc | Compositions comprising omega-3 fatty acids, 17-hdha and 18- hepe and methods of using same |
| ES2948444T3 (es) * | 2015-12-18 | 2023-09-12 | Afimmune Ltd | Composiciones que comprenden 15-HEPE |
| CN111481550A (zh) * | 2020-05-14 | 2020-08-04 | 王兆霖 | 含有噻托溴铵和阿福特罗的药物制剂 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05186342A (ja) * | 1992-01-10 | 1993-07-27 | Fujirebio Inc | 免疫調節作用を併せもつ抗炎症剤 |
| EP1296923B3 (en) * | 2000-02-16 | 2012-04-11 | The Brigham And Women's Hospital, Inc. | Aspirin-triggered lipid mediators |
| US20020188024A1 (en) * | 2000-08-23 | 2002-12-12 | Chilton Floyd H. | Fatty acid-containing emulsion with increased bioavailability |
| US20060160095A1 (en) * | 2002-12-13 | 2006-07-20 | Eirx Therapeutics Limited | Survivin |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| MX2007011273A (es) * | 2005-03-16 | 2007-11-08 | Meda Pharma Gmbh & Co Kg | La combinacion de anticolinergicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias. |
| EP2607358A4 (en) * | 2010-08-19 | 2014-01-29 | Univ Tokyo | NEW ANTI-INFLAMMATORY METABOLITE DERIVED FROM OMEGA-3 TYPE FATTY ACID |
| US10154977B2 (en) * | 2011-03-25 | 2018-12-18 | The Brigham And Women's Hospital, Inc. | Anti-inflammatory particles |
| US8293790B2 (en) * | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| US20120264705A1 (en) * | 2012-01-26 | 2012-10-18 | Dignity Sciences Limited | Antimicrobial compositions comprising 15-hetre and methods of use thereof |
| US20130267598A1 (en) * | 2012-02-23 | 2013-10-10 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same |
| NZ702325A (en) * | 2012-05-10 | 2016-09-30 | Solutex Na Llc | Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors |
| GB201301626D0 (en) * | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| MA41120A (fr) * | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
-
2015
- 2015-01-12 RU RU2016132762A patent/RU2685706C2/ru not_active IP Right Cessation
- 2015-01-12 JP JP2016563894A patent/JP2017505809A/ja not_active Ceased
- 2015-01-12 BR BR112016015997A patent/BR112016015997A2/pt not_active Application Discontinuation
- 2015-01-12 KR KR1020167021684A patent/KR20160132372A/ko not_active Application Discontinuation
- 2015-01-12 US US14/595,015 patent/US20150196521A1/en not_active Abandoned
- 2015-01-12 CN CN201580008336.5A patent/CN106029051A/zh active Pending
- 2015-01-12 EP EP15735225.3A patent/EP3091959A4/en not_active Withdrawn
- 2015-01-12 CA CA2935986A patent/CA2935986A1/en not_active Abandoned
- 2015-01-12 MX MX2016008953A patent/MX2016008953A/es unknown
- 2015-01-12 WO PCT/US2015/011054 patent/WO2015106215A2/en active Application Filing
- 2015-01-12 AU AU2015204531A patent/AU2015204531B2/en not_active Ceased
- 2015-01-12 SG SG11201605601UA patent/SG11201605601UA/en unknown
- 2015-01-12 SG SG10202000496XA patent/SG10202000496XA/en unknown
- 2015-01-12 RU RU2019110980A patent/RU2019110980A/ru unknown
-
2016
- 2016-07-06 IL IL246623A patent/IL246623A0/en unknown
- 2016-07-11 PH PH12016501371A patent/PH12016501371A1/en unknown
- 2016-07-22 US US15/217,008 patent/US20160324820A1/en not_active Abandoned
- 2016-08-08 ZA ZA2016/05492A patent/ZA201605492B/en unknown
-
2019
- 2019-08-15 JP JP2019149177A patent/JP2020002150A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017505809A5 (ja) | ||
| HRP20192299T1 (hr) | Liječenje nafld i nash | |
| JP2015078230A5 (ja) | ||
| JP2016511753A5 (ja) | ||
| JP2017509667A5 (ja) | ||
| RU2018114447A (ru) | Введение дейтерированных усилителей cftr | |
| JP2014507446A5 (ja) | ||
| JP2014515013A5 (ja) | ||
| JP2017537066A5 (ja) | ||
| JP2016510326A5 (ja) | ||
| JP2017513836A5 (ja) | ||
| JP2014218522A5 (ja) | ||
| BR112014003225A2 (pt) | profármacos de treprostinil ligados a veículo | |
| CY1119231T1 (el) | Θειαδιαζολιδινοδιονες ως αναστολεις της gsk-3 | |
| JP2017222722A5 (ja) | ||
| JP2013520405A5 (ja) | ||
| JP2015510916A5 (ja) | ||
| JP2016027060A5 (ja) | ||
| JP2016534081A5 (ja) | ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法 | |
| WO2017022962A8 (ko) | Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
| JP2016540015A5 (ja) | ||
| JP2018538273A5 (ja) | ||
| JP2015522603A5 (ja) | ||
| JP2016530291A5 (ja) | ||
| JP2016532632A5 (ja) |